supplementary table 1. impact of pretransplant factors on the incidence of pulmonary complications...
TRANSCRIPT
![Page 1: Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1](https://reader035.vdocument.in/reader035/viewer/2022072016/56649ee45503460f94bf2a07/html5/thumbnails/1.jpg)
Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications
Factor Univariate RR (95% CI) P-value Multivariate RR*1 (95% CI) P-value Multivariate RR*1*2 (95% CI) P-value
Age< 42 years 1.00 ≥ 42 years 1.31 (0.86-1.99) 0.21
SexMale 1.00 Female 0.65 (0.41-1.01) 0.06
Disease risk*3
Low 1.00 1.00 1.00 High 1.57 (1.03-2.38) 0.04 1.61 (1.04-2.48) 0.03 1.60 (1.04-2.46) 0.03
Stem cell source
Bone marrow 1.00 Peripheral blood 0.48 (0.22-1.06) 0.07 Cord blood 1.52 (0.87-2.66) 0.14
Donor typeRelated 1.00 1.00 1.00 Unrelated 2.10 (1.22-3.62) < 0.01 2.09 (1.20-3.67) 0.01 1.93 (1.09-3.41) 0.02
Conditioning regimenMyeloablative 1.00 Reduced intensity 1.53 (0.98-2.38) 0.06
GVHD prophylaxisCyclosporine-based 1.00 Tacrolimus-based 1.18 (0.79-1.76) 0.44
Smoking dose (BI)0 1.00 1.00 1-399 1.51 (0.92-2.47) 0.11 1.43 (0.87-2.36) 0.16 ≥ 400 2.02 (1.21-3.35) < 0.01 1.78 (1.06-3.00) 0.03
Smoking dose (BI*2 per 10) 1.01 (1.00-1.01) < 0.01 1.01 (1.00-1.01) 0.02 Abbreviations: RR, relative risk; CI, confidence interval; BI, Brinkman index*1: The variables with P < 0.05 on univariate analysis were subjected to multivariate analysis.*2: BI was treated as a continuous variable*3: Low-disease risk included acute leukemia in first complete resmission (CR), chronic myelogenous leukemia in first chronic phase, myelodysplasia refractory anemia, malignant lymphoma in CR and non-malignant hematologic diseases; while high-disease risk included all other diagnoses.
![Page 2: Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1](https://reader035.vdocument.in/reader035/viewer/2022072016/56649ee45503460f94bf2a07/html5/thumbnails/2.jpg)
Supplementary Table 2. Causes of pulmonary complications
Never smokers(N=31)
Smokers
Low-dose (BI, 1-399)(N=31)
High-dose (BI ≥400)(N=28)
Infection
Pneumonia 21 (17%) 23 (25%) 22 (33%)
Tuberculosis 1 (1%) 0 1 (2%)
Non-infection
Organizing pneumonia 4 (3%) 3 (3%) 2 (3%)
Interstitial pneumonia 4 (3%) 1 (1%) 1 (2%)
Bronchiolitis obliterans 1 (1%) 3 (3%) 1 (2%)
Pulmonary veno-occlusive disease 0 1 (1%) 0
Lung cancer 0 0 1 (2%)
Abbreviation: BI, Brinkman index
![Page 3: Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1](https://reader035.vdocument.in/reader035/viewer/2022072016/56649ee45503460f94bf2a07/html5/thumbnails/3.jpg)
Supplementary Table 3. Causes of death (N = 122)
Never smokers(N=58)
Smokers
Low-dose (BI, 1-399)(N=37)
High-dose (BI ≥400)(N=37)
Disease progression 19 (33%) 11 (30%) 13 (35%)
Non-relapse mortalityPulmonary Pneumonia 14 (24%) 5 (14%) 10 (27%) Bronchiolitis obliterans 0 1 (3%) 0 Alveolar hemorrhage 0 1 (3%) 1 (3%) Interstitial pneumonia 1 (2%) 1 (3%) 0
Infections other than pneumonia 10 (17%) 7 (18%) 3 (7%)
GVHD 3 (5%) 3 (8%) 4 (11%)
VOD/TMA 3 (5%) 2 (5%) 0
Organ failure 3 (5%) 3 (8%) 3 (7%)
Others 5 (9%) 3 (8%) 3 (7%) Abbreviations: BI, Brinkman index; GVHD, graft-versus-host disease; VOD, veno-occlusive disease; TMA, thrombotic microangiopathy